Publications by authors named "P Klekotka"
T cells are involved in protective immunity against numerous viral infections. Data regarding functional roles of human T cells in SARS-CoV-2 (SARS2) viral clearance in primary COVID-19 are limited. To address this knowledge gap, we assessed samples for associations between SARS2 upper respiratory tract viral RNA levels and early virus-specific adaptive immune responses for 95 unvaccinated clinical trial participants with acute primary COVID-19 aged 18-86 years old, approximately half of whom were considered at high risk for progression to severe COVID-19.
View Article and Find Full Text PDFArticle Synopsis
- - Current treatments for autoimmune diseases often fail to achieve long-term remission, prompting interest in therapies that restore balance in the immune system, known as immune resolution; however, there's no clear consensus on how to evaluate these therapies in clinical trials.
- - A systematic literature review (SLR) was conducted using established guidelines to explore expert opinions and previous studies on immune resolution in five autoimmune diseases: asthma, atopic dermatitis, rheumatoid arthritis, systemic lupus erythematosus, and ulcerative colitis; this involved searching databases and conference proceedings from 2013 to 2023.
- - The SLR included 26 publications and found that expert opinions tended to lack specific measures for assessing immune resolution but suggested potential targets and biomarkers for future therapy
Background: Anti-SARS-CoV-2 monoclonal antibodies (mAbs) have played a key role as an anti-viral against SARS-CoV-2, but there is a potential for resistance to develop. The interplay between host antibody responses and the development of monoclonal antibody (mAb) resistance is a critical area of investigation. In this study, we assessed host neutralizing antibody (nAb) responses against both ancestral virus and those with treatment-emergent E484K bamlanivimab resistance mutations.
View Article and Find Full Text PDFIntroduction: The monoclonal antibody therapies bamlanivimab (BAM) + etesevimab (ETE) received emergency use authorization (EUA) from the US Food and Drug Administration (February 9, 2021) for treatment of mild-to-moderate COVID-19. The EUA of BAM + ETE was revoked (December 14, 2023) due to the high prevalence of BAM + ETE-resistant variants of SARS-CoV-2. Efficacy and safety of 700/1400 mg and 2800/2800 mg BAM + ETE are well established and published; however, efficacy and safety of 350/700 mg BAM + ETE have not been disclosed to date.
View Article and Find Full Text PDFArticle Synopsis
- The study evaluates two different antibody detection assays (MSD and Bio-Plex Pro) for their effectiveness in measuring antibodies against SARS-CoV-2, focusing on various antibody types (IgG, IgM, IgA) and antigens (RBD, N).
- Results showed high concordance (90.5% for anti-RBD IgG and 87% for anti-N IgG) in determining sample status as positive or negative across the two assays, indicating they can reliably assess immune responses.
- The research also found that participants treated with the monoclonal antibody bamlanivimab showed reduced IgG responses compared to those given a placebo, suggesting the treatment affects immune response